Anondita Medicare Capital Structure Change
Anondita Medicare Limited has reinstated its previous rights issue corrigendum. The issue size is now confirmed at 9,58,166 equity shares, aggregating to ₹91.03 Crore.
- Value
- ₹91.03 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Anondita Medicare Limited has reinstated its previous rights issue corrigendum. The issue size is now confirmed at 9,58,166 equity shares, aggregating to ₹91.03 Crore.
Anondita Medicare Limited issued a corrigendum to its Rights Issue, revising the total issue size to ₹91.03 Crore and adjusting the allocation for general corporate purposes.
Anondita Medicare Limited clarified procedures for handling odd lots of Rights Entitlements and shares during its ongoing Rights Issue. No new transaction value is involved.
Anondita Medicare Limited has issued the notice for its 3rd Annual General Meeting scheduled for September 29, 2026. The meeting will address ordinary and special business resolutions.
Anondita Medicare Limited has been declared the L1 bidder by the Central Medical Services Society for supplying 8.01 crore pieces of condoms.
Anondita Medicare Limited announced a Rights Issue of 9.58 lakh equity shares to raise up to ₹91.01 Crore. The issue opens on September 9, 2026.
Anondita Medicare Limited has appointed M/s Mohit Singhal & Associates as the Secretarial Auditor for the financial year 2026-2027. This is a routine secretarial appointment.
Anondita Medicare Limited has fixed September 02, 2026, as the record date for determining shareholders eligible for its Rights Issue of Equity Shares.
Anondita Medicare Limited approved a rights issue of 9,58,000 equity shares at an issue price of ₹950 per share.
Anondita Medicare Limited received in-principle approval from NSE for a proposed Rights Issue. The issue aggregates up to ₹109.78 Crore at a face value of ₹10 per share.